GlassScriptPhysician profile
Brian S Kahan
NPI 1740210814
$1,584.56
in general payments reported to CMS, 2019-2025
21 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $161 · 2021: $434 · 2022: $118 · 2023: $128 · 2024: $151 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $224.03 | 2019-2023 | Proclaim |
| Abbvie INC. | $213.01 | 2021-2025 | |
| Boston Scientific Corporation | $211.53 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Mesoblast, INC. | $177.57 | 2025 | Ryoncil |
| Stryker Corporation | $160.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.90 | 2019 | |
| Allergan, INC. | $100.03 | 2019-2021 | |
| Depuy Synthes Sales INC. | $75.94 | 2024 | Monovisc, Orthovisc |
| Medtronic, INC. | $42.43 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $36.60 | 2023-2024 | Ztlido |
| Nevro Corp. | $30.46 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $29.51 | 2022 | |
| Averitas Pharma INC. | $29.47 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $20.54 | 2025 | |
| Tms Neurohealth Centers INC. | $20.37 | 2025 | Tms Neurohealth Centers INC. |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.32 | 2023 | Xtampza |
| Acelrx Pharmaceuticals, INC. | $16.27 | 2019 | |
| Pfizer INC. | $14.81 | 2019 | |
| Horizon Therapeutics Plc | $14.19 | 2019 | |
| Medtronic Vascular, INC. | $13.89 | 2020 | |
| West Therapeutics Development, LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.